September 5, 2014 -- Hainan Sinotau Pharma and Navidea Biopharma of the US struck a deal under which Sinotau will have rights to develop and commercialize Lymphoseek® Injection in China. Lymphoseek is a radiopharmaceutical developed by Navidea to detect lymph nodes in patients with breast cancer or melanoma. Sinotau will be responsible for obtaining China approval of Lymphoseek. It will also be liable for up to $2.5 million in milestones, including a $300,000 upfront payment, along with payments based on unit sales and a royalty on sales.
Help employers find you! Check out all the jobs and post your resume.
